ANA RAYGOZA: Open Payments
NPI 1437313913 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,933 in 108 payments from 18 companies in 2025. Trend: 2023 $1,716 · 2024 $2,063 · 2025 $1,933
Food & beverage: $1,933
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $451 |
| Janssen Biotech, Inc. | 24 | $419 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 17 | $298 |
| Lilly USA, LLC | 8 | $154 |
| Celltrion USA Inc. | 5 | $116 |
| Ardelyx, Inc. | 4 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $63 |
| Novo Nordisk Inc | 3 | $54 |
| Gilead Sciences, Inc. | 2 | $52 |
| Ipsen Biopharmaceuticals, Inc | 3 | $48 |
Products named: TREMFYA, XIFAXAN, LINZESS, RINVOQ, OMVOH, VEGZELMA, IBSRELA, EOHILIA.
Industry payments across TX — which companies pay providers there.
